Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France.
Pediatr Blood Cancer. 2023 Nov;70(11):e30627. doi: 10.1002/pbc.30627. Epub 2023 Aug 14.
Three-dimensional conformal RT (3D-RT) techniques are gold standard for post-operative flank radiotherapy (RT) in paediatric renal tumours. Recently, highly conformal RT (HC-RT) techniques have been implemented without comparative clinical data. The main objective of this multicentre study was to compare locoregional control (LRC) in children treated either with HC-RT or 3D-RT techniques.
Patients treated with post-operative flank RT for renal tumour registered in the national cohort PediaRT between March 2013 and September 2019 were included. Treatment and follow-up data, including toxicities and outcomes, were retrieved from the database. LRC was calculated, and dose reconstruction was performed in case of an event.
Seventy-nine patients were included. Forty patients were treated with HC-RT and 39 with 3D-RT. Median follow-up was 4.5 years. Three patients had locoregional failure (LRF; 4%). HC-RT was not associated with a higher risk of LRF. Three-year LRC were 97.4% and 94.7% in the HC-RT and 3D-RT groups, respectively. The proportion of planning target volumes receiving 95% or more of the prescribed dose did not significantly differ between both groups (HC-RT 88%; 3D-RT 69%; p = .05). HC-RT was better achieving dose constraints, and a significant mean dose reduction was observed in the peritoneal cavity and pancreas associated with lower incidence of acute gastrointestinal toxicity.
LRF after post-operative flank RT for renal tumours was rare and did not increase using HC-RT versus 3D-RT techniques. Dose to the pancreas and the peritoneal cavity, as well as acute toxicity, were reduced with HC-RT compared to 3D-RT.
三维适形放疗(3D-RT)技术是儿童肾肿瘤术后放疗的金标准。最近,高适形放疗(HC-RT)技术已经得到应用,但缺乏比较的临床数据。本多中心研究的主要目的是比较儿童接受 HC-RT 或 3D-RT 技术治疗后的局部区域控制(LRC)。
纳入 2013 年 3 月至 2019 年 9 月期间在国家队列 PediaRT 中接受术后肾肿瘤侧腹放疗的患者。从数据库中检索治疗和随访数据,包括毒性和结果。计算 LRC,并在发生事件时进行剂量重建。
共纳入 79 例患者。40 例患者接受 HC-RT 治疗,39 例患者接受 3D-RT 治疗。中位随访时间为 4.5 年。3 例患者发生局部区域复发(LRF;4%)。HC-RT 与 LRF 风险增加无关。HC-RT 和 3D-RT 组的 3 年 LRC 分别为 97.4%和 94.7%。两组计划靶区接受处方剂量 95%以上的比例无显著差异(HC-RT 组 88%;3D-RT 组 69%;p=0.05)。HC-RT 更好地实现了剂量限制,并且观察到与较低的急性胃肠道毒性发生率相关的腹腔和胰腺的平均剂量显著降低。
术后侧腹放疗治疗肾肿瘤后的局部区域复发罕见,使用 HC-RT 与 3D-RT 技术相比并未增加。与 3D-RT 相比,HC-RT 降低了胰腺和腹腔的剂量以及急性毒性。